TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26242893
Drug: Single-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose radiotherapy (8 Gy)
Study: 18418314
Drug: Antioxidant therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy, hydration regimens, choice of contrast agents
Study: 17165278
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate DPI 100 microg twice daily
Study: 17165278
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate DPI (both doses)
Study: 11069325
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.)
Study: 11069325
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy plus ecabet sodium (1 g b.d.)
Study: 11069325
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy plus ecabet sodium (2 g b.d.)
Study: 9059199
Drug: Ketoprofen 1
Normalized name: ketoprofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 1 mg kg-1 i.v. after induction followed by an infusion of ketoprofen 1 mg kg-1 over 2 h
Study: 8419248
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mL = 15 mg)
Study: 27130793
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy plus radiation therapy to 70 Gy
Study: 22067254
Drug: MagPro™ (Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MagPro™ (Mg cream)
Study: 19018977
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg
Study: 7153153
Drug: Atropine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.0 mg
Study: 28252875
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (0.1%) four times a day for 7 days before surgery and discontinued 30 days after surgery
Study: 28252875
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (0.1%)
Study: 23144450
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg biweekly
Study: 23144450
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg monthly
Study: 21448308
Drug: Flurbiprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (2 x 100 mg) and tramadol (4 x 100 mg)
Study: 21448308
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received tramadol (4 x 100 mg)
Study: 19257824
Drug: Ibandronate (IBN)
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (IBN) 2 mg intravenously every 3 months
Study: 16015459
Drug: Autogenic training
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic training (AT) for 10 weeks, with weekly sessions and daily practice at home
Study: 12581053
Drug: Boost intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boost intervention in conservative treatment
Study: 20948238
Drug: Nilvadipine 4
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 4 mg/day for ≥30 months
Study: 20948238
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tocopherol nicotinate 300 mg/day, helenien 15 mg/day, or no medication) for ≥30 months
Study: 20948238
Drug: Nilvadipine 4
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 4 mg/day for total observational period
Study: 16458337
Drug: Co-trimoxazole prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole prophylaxis (sulphamethoxazole 800 mg/trimethoprim 160 mg daily)
Study: 1451052
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5‐fluorouracil (1000 mg/m2 for 48 hours)
Study: 1451052
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 5‐fluorouracil (500 mg/m2 x 2 in 48 hours)
Study: 1451052
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 5‐fluorouracil
Study: 17966969
Drug: Metformin (M,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (M, n = 13)
Study: 17966969
Drug: Gliclazide (G,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (G, n = 13)
Study: 7480274
Drug: Betamethasone 6
Normalized name: betamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 6 mg IM preoperatively
Study: 2381618
Drug: 1.6% terconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6% terconazole cream
Study: 7030835
Drug: CDCA (12‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (12‐15 mg/kg/day)
Study: 7030835
Drug: UDCA (5‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (5‐6 mg/kg/day)
Study: 7030835
Drug: UDCA (10‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (10‐12 mg/kg/day)
Study: 28342637
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus short-term prednisone (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18; prednisone 0.5 or 1.0 mg/kg per day tapered over 3 or 6 months)
Study: 28342637
Drug: Prednisone alone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone alone (1.0 or 1.5 mg/kg per day tapered over 12 or 18 months)
Study: 19119169
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel (20 percent benzocaine gel) applied for 2 minutes
Study: 15155717
Drug: 6% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% CHO solution before and during training and 20% solution post-exercise (H-CHO trial)
Study: 15155717
Drug: 2% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHO solution before and during training and 2% solution post-exercise (L-CHO trial)
Study: 15155717
Drug: L-CHO trial
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-CHO trial
Study: 11439734
Drug: Rofecoxib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (5 to 50 mg)
Study: 9603669
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied 1% beta‐LHA formulation
Study: 3403064
Drug: Beta-carotene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (180 mg/week)
Study: 3403064
Drug: Beta-carotene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (180 mg/week) plus vitamin A (100,000 IU/week)
Study: 26613819
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg misoprostol with 10 units of oxytocin
Study: 16167707
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Study: 16167707
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Study: 3219882
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pinaverium bromide intravenously
Study: 3219882
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg pinaverium bromide intravenously
Study: 23775505
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at steady-state effect-site concentrations of 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml
Study: 23775505
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three surrogate parameters (pupil diameter, light reflex amplitude, and tracking performance)
Study: 21569011
Drug: Context therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Context therapy
Study: 16800900
Drug: Whole-brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiotherapy plus chemotherapy
Study: 11919130
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x NPH daily
Study: 10503820
Drug: Long-term acid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term acid inhibition therapy
Study: 10503820
Drug: Long-term acid-inhibitory
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term acid-inhibitory therapy for an average of three years
Study: 2260008
Drug: Hypoxyradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxyradiotherapy with a mixture of nitrogen and oxygen containing 8.0 to 8.5% O2, increased external irradiation doses by 40%
Study: 25166480
Drug: Ecopipam (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (50 to 100 mg/d as needed)
Study: 22940562
Drug: Prescribed opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed opioid dose
Study: 22940562
Drug: Patient-reported opioid
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported opioid dose
Study: 17181890
Drug: Dairy group
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy group (DG: n 39) receiving approximately 1200 mg calcium/d and 7.5 microg vitamin D3/d through fortified dairy products
Study: 17181890
Drug: Calcium-supplemented group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-supplemented group (CaG: n 26) provided with a calcium supplement of 600 mg/d
Study: 14523483
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with stent implantation and GP IIb/IIIa receptor inhibitors in patients with NSTEACS (group A)
Study: 10813102
Drug: Lovelle (desogestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovelle (desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg)
Study: 10813102
Drug: Valette (dienogest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valette (dienogest 2.0 mg plus ethinyl estradiol 0.03 mg)
Study: 8785183
Drug: Oxymetholone monotherapy
Normalized name: Oxymetholone
DrugBank: Oxymetholone (DB06412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetholone monotherapy
Study: 8785183
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Oxymetholone monotherapy and Oxymetholone plus ketotifen)
Study: 7091039
Drug: EG AA
Normalized name: Ethinyl Estradiol and Norethindrone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG AA group, 3 eggs + 2 g ascorbic acid
Study: 7091039
Drug: AA group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA group, 2 g ascorbic acid
Study: 31912490
Drug: Community-based couple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based couple therapy
Study: 27669288
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (6000 IU daily for 12 weeks)
Study: 27669288
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement (for those with vitamin D status over 75 nmol/L)
Study: 24731234
Drug: Group care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group care (GC) treatment as usual (TAU)
Study: 21115589
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (5‐methyltetrahydrofolate 560 μg, vitamin B‐6 3 mg, vitamin B‐12 20 μg)
Study: 21115589
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acids (600 mg of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1)
Study: 18784373
Drug: Tocilizumab (anti-IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (anti-IL-6 receptor antibody)
Study: 16005273
Drug: Oral salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salmon calcitonin (sCT) 1.0 mg
Study: 16005273
Drug: Oral salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salmon calcitonin (sCT) (0.15, 0.4, 1.0, or 2.5 mg)
Study: 10095141
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 50% sucrose solution
Study: 10095141
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml sterile water (placebo)
Study: 1317687
Drug: Lisinopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (mean dose 35 mg qd)
Study: 1317687
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean dose 54 mg bid)
Study: 23157083
Drug: Local instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local instillation of 0.75% ropivacaine (20 ml)
Study: 19592206
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (20,000 IU, 10 daily doses starting from the day of trauma)
Study: 19017587
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of daily rifampin therapy
Study: 19017587
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of daily isoniazid therapy
Study: 15747247
Drug: 1x10(5) TCID(50)
Normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x10(5) TCID(50) bPIV3 vaccine
Study: 15747247
Drug: 1x10(6) TCID(50)
Normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x10(6) TCID(50) bPIV3 vaccine
Study: 12451727
Drug: Ribavirin 1200
Normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1200 mg daily
Study: 10600085
Drug: Multidisciplinary antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary antimicrobial treatment team intervention
Study: 29305400
Drug: Escalated drug
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalated drug therapy in amio-refractory patients
Study: 29305400
Drug: Escalated drug
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalated drug therapy in sotalol-refractory patients
Study: 28083797
Drug: Oral fludrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludrocortisone
Study: 28083797
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral fludrocortisone and intravenous hydrocortisone
Study: 22245630
Drug: Saracatinib 50
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 50 mg/day
Study: 22245630
Drug: Saracatinib 125
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 125 mg/day
Study: 22245630
Drug: Saracatinib 175
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 175 mg/day
Study: 15947502
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 2% with intracameral lidocaine 1%
Study: 15947502
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical anesthesia (bupivacaine 0.5, oxybuprocaine, and diclofenac eyedrops) with intracameral lidocaine 1%
Study: 12889589
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral broad spectrum Ampicillin/Amoxicillin and Erythromycin therapy during conservative management of pPROM before 32 weeks' gestation
Study: 8997659
Drug: Small particle
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small particle size tetracycline in gel
Study: 8997659
Drug: Large particle
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large particle size tetracycline in gel
Study: 1631985
Drug: Simple CPAP
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple CPAP with a 10 l latex balloon reservoir
Study: 29422181
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention (four consecutive weekly 1-hour music classes)
Study: 26787792
Drug: Sugammadex (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (0.25, 0.5, 0.75, 1.0, or 1.25 mg kg(‐1) i.v.)
Study: 26787792
Drug: Neostigmine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (10, 25, 40, 55, or 70 µg kg(‐1) i.v.)
Study: 20816042
Drug: Armodafinil 50
Normalized name: armodafinil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 50 mg
Study: 17432112
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or statins
Study: 16087943
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (12 doses) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Study: 24647391
Drug: Aromatic amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic amino acid (AAA) supplementation (330 mg · kg(‐1) · d(‐1))
Study: 22334767
Drug: Individualized training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized training program designed to improve activity of daily living (ADL) and physical capacity, lasting for 3 months.
Study: 8665880
Drug: Midazolam followed
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam followed by vecuronium 0.1 mg kg‐1
Study: 8665880
Drug: Midazolam followed
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam followed by atracurium 0.5 mg kg‐1
Study: 2667526
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of luffa operculata D4, kalium bicromicum D4 and cinnabaris D3
Study: 2667526
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of kalium bicromicum D4 and cinnabaris D3
Study: 1002948
Drug: Methylphenidate combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate combined with behavior therapy
Study: 30830727
Drug: pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate 0.2 mg/d
Study: 30830727
Drug: pemafibrate 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate 0.4 mg/d
Study: 30830727
Drug: placebo/pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/pemafibrate 0.2 mg/d
Study: 25336333
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m² daily for 5 days
Study: 25336333
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m² daily for 5 days plus oral valproic acid 50 mg/kg daily for 7 days
Study: 22451457
Drug: No compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: No compression treatment
Study: 15277160
Drug: Cactus pear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cactus pear fruit (250 g fresh fruit pulp)
Study: 15277160
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (75 mg twice daily)
Study: 3318445
Drug: Ibuprofen 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1,200 mg
Study: 28985142
Drug: Sour cherries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour cherries (500 g daily for 30 days)
Study: 28985142
Drug: Apples (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apples (500 g daily for 30 days)
Study: 26120851
Drug: Didactic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didactic injection risk intervention
Study: 20659602
Drug: Probiotic prophylaxis
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic prophylaxis (1 capsule of Probaclac Vaginal containing 8 billion CFUs of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus)
Study: 18834368
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (monthly 1-hour education programme)
Study: 15827569
Drug: Citalopram (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (7.5 mg intravenously)
Study: 11978284
Drug: Preoperative recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative recombinant human erythropoietin therapy
Study: 11978284
Drug: No erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No erythropoietin therapy (Control)
Study: 8626885
Drug: Nefazodone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (200 mg every 12 hours) and Propranolol (40 mg every 12 hours)
Study: 6448025
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin hydrochloride hydrate applied twice daily for eight weeks